Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 7, 2022; 28(5): 517-531
Published online Feb 7, 2022. doi: 10.3748/wjg.v28.i5.517
Viral hepatitis: Innovations and expectations
Simona Leoni, Alberto Casabianca, Benedetta Biagioni, Ilaria Serio
Simona Leoni, Alberto Casabianca, Benedetta Biagioni, Ilaria Serio, Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy
Author contributions: Leoni S and Serio I reviewed the literature and wrote the paper; Casabianca A and Benedetta B contributed to manuscript drafting; all authors issued final approval for the version to be submitted.
Conflict-of-interest statement: All authors has nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Simona Leoni, MD, PhD, Doctor, Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna 40138, Italy. simona.leoni@aosp.bo.it
Received: April 30, 2021
Peer-review started: April 30, 2021
First decision: June 30, 2021
Revised: July 14, 2021
Accepted: January 17, 2022
Article in press: January 17, 2022
Published online: February 7, 2022
Processing time: 269 Days and 15.4 Hours
Core Tip

Core Tip: Viral hepatitis is a known worldwide health problem, with a risk of evolution in chronic liver disease. Novel therapies have shown increased efficacy in curing the hepatitis C virus (HCV), with the goal of HCV elimination by 2030. New concurrent interest in hepatitis B virus (HBV) curative therapies has been recently registered: New antivirals targeting different steps of HBV life cycle and immune modulators. In hepatitis D, the improved knowledge of the life cycle has facilitated the development of some direct-acting agents, more effective than interferon-based therapies. New studies are required to improve the treatment of hepatitis E.